The P-III (STARGLO) trial assesses the safety, tolerability & efficacy of Columvi (glofitamab) combined with gemcitabine + oxaliplatin (GemOx) vs rituximab + GemOx for treating r/r DLBCL patients administered with at least one previous line of therapy & not eligible for autologous stem cell transplant
The 1EP of the study includes overall survival while the 2EPs include progression-free survival, complete response rate, objective response rate as well as the duration of objective response
The study showed a consistent safety profile and reached the 1EP depicting those patients who received Columvi in combination with GemOx lived longer. The results will be highlighted at a future medical meeting
Ref: Roche | Image: Roche
Related News:- Roche’s Columvi (glofitamab) Receives EC’s Conditional Marketing Authorization for Relapsed or Refractory Diffuse Large B-cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
